arrow
E

Egils Vjaters

Pauls Stradins Clinical University Hospital
H指数:17
被引数:2,302

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Darolutamide Plus Androgen-deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase 3 ARANOTE Trial

达罗鲁胺联合雄激素剥夺疗法在ARANOTE III期临床试验中针对转移性激素敏感前列腺癌的疾病体积和风险亚组研究

2026-08-130
PRE
Pain and health-related quality-of-life outcomes with darolutamide in metastatic hormone-sensitive prostate cancer (ARANOTE): secondary and exploratory analyses of a multicentre, randomised, placebo-controlled, phase 3 trial

达罗鲁胺治疗转移性激素敏感型前列腺癌的疼痛和健康相关生活质量结局(ARANOTE):一项多中心、随机、安慰剂对照III期试验的次要和探索性分析

2026-04-090
PRE
A Deep Prostate-specific Antigen Response to Darolutamide plus Androgen Deprivation Therapy Is Associated with Better Clinical Outcomes in the Phase 3 ARANOTE Trial in Patients with Metastatic Hormone-sensitive Prostate Cancer

在ARANOTE III期临床试验中,对于转移性激素敏感性前列腺癌患者,达罗他胺联合雄激素剥夺疗法可引起深度前列腺特异性抗原反应,并与更优的临床结局相关。

2025-08-220
OAAI
Efficacy and safety of darolutamide plus androgen-deprivation therapy (ADT) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) from the phase III ARANOTE trial

达罗他胺联合雄激素剥夺疗法(ADT)在转移性激素敏感前列腺癌(mHSPC)患者中的有效性和安全性:来自III期ARANOTE试验的数据

2024-09-011
PRE
Safety and tolerability of long-term treatment with darolutamide in patients with metastatic castration-resistant prostate cancer
2023-10-260
OAAI
Efficacy and safety outcomes of darolutamide in patients with non-metastatic castration-resistant prostate cancer with comorbidities and concomitant medications from the randomised phase 3 ARAMIS trial

来自ARAMIS随机3期试验的达鲁柳胺对伴合并症和合并用药的非转移性去势抵抗性前列腺癌患者的疗效和安全性

2023-10-014
OA
Efficacy and Safety of Darolutamide in Patients with Nonmetastatic Castration-resistant Prostate Cancer Stratified by Prostate-specific Antigen Doubling Time: Planned Subgroup Analysis of the Phase 3 ARAMIS Trial
2023-03-019
OA
Efficacy and Safety of Darolutamide in Patients with Nonmetastatic Castration-resistant Prostate Cancer Stratified by Prostate-specific Antigen Doubling Time: Planned Subgroup Analysis of the Phase 3 ARAMIS Trial (vol 83, pg 212, 2023)
2023-02-011
OA
Darolutamide and health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: An analysis of the phase III ARAMIS trial

Darolutamide与非转移性去势抵抗性前列腺癌患者的健康相关生活质量: 对ARAMIS III期试验的分析

2021-09-0129
OA